<DOC>
	<DOC>NCT01469910</DOC>
	<brief_summary>The purpose of this study is to assess the safety and pharmacokinetics of single ascending doses of Simotinib Hydrochloride in healthy subjects.</brief_summary>
	<brief_title>Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Simotinib Hydrochloride in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy , male or female subjects Age of 18 to 45 years Body Mass Index (BMI) of 19 to 24 kg/m2; and a total body weight &gt; 50 kg for male, &gt; 45 kg for female Written informed consent signed and dated by the subject Subjects who are willing and able to comply with study procedures Any clinically significant disease or surgery within 4 weeks prior to the beginning of the study Known hypersensitivity to the study drug or similar drugs History of any serious disease, including but not limited to circulatory system, endocrine system, central nervous system, hematology, immunology, metabolic diseases and psychiatric disorders History of gastrointestinal, hepatic, and renal diseases, affecting drug absorption and metabolism Any clinically significant abnormal clinical laboratory tests Abnormal ECG or vital signs A positive test for HIV antibody A positive prestudy Hepatitis B surface antigen or positive Hepatitis C antibody result History of alcohol consumption within six months of the study defined as: an average weekly intake of &gt; 14 units History of regular tobacco use or nicotine containing products within three months prior to screening Consumption of too much tea or coffee (&gt; 8 cups/day) Use of any drug, which inhibits or induces hepatic drug metabolism, within 30 days prior to the beginning of the study Use of any drug within 14 days prior to the beginning of the study Participate in other clinical trials within 30 days prior to the beginning of the study Blood donation within 30 days of dosing All female subjects must not be of childbearing potential Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>